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Abstract

INHIBITION OF mTOR SIGNALING PROTECTS AGAINST MYOCARDIAL
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Acute myocardial infarction (AMI) is the leading cause of death worldwide.
Currently, the best method of treating cardiac ischemia is early reperfusion which, itself,
induces myocardial damage. The mTOR complex is a key regulator of cardioprotection
against cell stressors. We hypothesized that reperfusion therapy with Rapamycin, a potent
mTOR inhibitor, would reduce infarct size in adult mouse hearts. Rapamycin was
administered at the onset of reperfusion following 30 min in situ LAD ligation. After 24

hours of reperfusion, myocardial infarct size and apoptosis were significantly reduced in
rapamycin-treated mice compared to control. Rapamycin inhibited pro-apoptotic protein
Bax and phosphorylation of ribosomal protein S6 (target of mTORC1), while it induced
phosphorylation of AKT (target of mTORC2). Rapamycin also induced phosphorylation of
ERK, while significantly reduced phosphorylation of p38. Thus, our study shows that
reperfusion therapy with Rapamycin provides cardioprotection through induction of the
phosphorylation of Akt and ERK.

Introduction

1.1 Ischemic Heart Disease
Of the vast amount of tissue types in the human body, few respond as adversely to
hypoxic conditions as cardiac muscle. Originally thought to only be a major issue in
developing nations, ischemic heart disease was identified as the world’s leading cause of
death in 2010.1 In addition to the staggering loss of life to initial myocardial infarction
(MI), individuals who survive a heart attack see a dramatic decline in cardiac function,
often resulting in heart failure (Figure 1). Patients such as these become dependent on
medical interventions for the rest of their lives, taking a tremendous economic toll on the
healthcare system; as the world’s population has increased, so too has this burden.2 Thus, it
is of no surprise that cardioprotective therapies have garnered a great deal of attention in
the scientific community. To date, prompt reoxygenation of ischemic tissue has proven to
be the most effective method of minimizing infarct size; a process known as reperfusion.3,4
However, this treatment brings with it it’s own set of challenges in the form of infarctforming reperfusion injury.5 The key, then, is to identify the process by which this injury
occurs, and how to best reduce its negative impact on the myocardium.

1.2 Mechanisms of Ischemic Injury
Ischemia/Reperfusion injury (I/R) is best characterized by the infarct region
produced by both the ischemic state of the myocardium, and the damaging effects of
reperfusion therapy. Ischemia occurs when a tissue is not perfused properly, resulting in
1

Figure 1. Complications following cardiac ischemia. The lethal downwards spiral that
can arise from a single ischemic event in the heart. The myocardial damage produced by
ischemia creates a functionless infarct region within the myocardium. As initial attempts to
compensate for the damage fail, the heart may undergo adverse remodeling processes,
resulting in cardiomyopathies that impede cardiac function. When the heart is no longer
able to properly function, the patient suffers from heart failure, which can promote further
opportunities for cardiac damage.
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inadequate oxygenation of said tissue. In the heart, this is most commonly due to coronary
artery occlusion arising from hardened plaque deposits that accumulate on the arterial wall
over time (atherosclerosis).6 Because these vessels are responsible for distributing
oxygenated blood throughout the myocardium, their occlusion results in the body’s
primary blood pumping organ being starved of oxygen.
Cardiomyocytes are unique in their extraordinary level of contractile activity.
Barring pathologic conditions, these cells work ceaselessly and, as such, have massive
energy demands. In order to supply themselves with the vast amount of ATP required for
their constant function, their cytosol is highly mitochondria-dense.7,8 Ordinarily, oxygen
functions as the terminal electron acceptor of the electron transport chain (ETC) located
within the inner mitochondrial membrane. The reduction of oxygen to water is integral in
establishing the proton gradients required for oxidative phosphorylation and proper ATP
production.7,8 When the cell becomes hypoxic, aerobic respiration is no longer available,
and the mitochondria falls back to less efficient anaerobic glycolysis, initiating a cascade
of events that defines ischemic injury. Lactate, a by-product of this cycle, is an acidic
compound that begins to flood the cytosol, decreasing the intracellular pH of the myocyte.
The ensuing increase in [H+]i serves to drive the cell membrane-bound Na+-H+ antiporter
to draw an influx of Na+ ions into the cell. Under physiologic conditions, these Na+ ions
would simultaneously be transported back out by the 3Na+-2K+-ATPase, but inadequate
ATP generation dictates otherwise. Thus, an alternate compensatory mechanism is
activated by an additional membrane-bound antiport channel: The 2Na+-Ca+2 exchanger.5,73

10

The net result is a massive [Ca+2]i spike under ischemic conditions. While anaerobic

glycolysis serves as a ‘fallback’ pathway during hypoxia, by no means it adequately
supplies the cardiomyocyte with enough ATP to properly function. Consequently, basic
metabolic needs are not met, and degradative enzymes such as proteases and
phospholipases further inhibit mitochondrial function. A rapid decline in cellular integrity
ensues, as ionic gradients are no longer able to be maintained, and contracture ceases. Left
unchecked, ischemia will continue indefinitely, causing irreparable damage to the heart
that will prevent proper function.

1.3 Mechanisms of Reperfusion Injury
Early reoxygenation of the heart, known as reperfusion, is currently the most
effective therapeutic method of treating patients suffering from ischemia.11,12 While it is a
necessary and definitive end to the ongoing ischemia, reperfusion imposes it’s own set of
infarction-producing challenges. In this sense, reperfusion therapy functions as a doublededged sword: It is necessary to avoid the near-certain death afforded by ischemia, yet it
must be controlled carefully to minimize further infarct size progression.12 In order to fully
understand the mechanisms of reperfusion injury, it is first important to realize the
importance of the Mitochondrial Permeability Transition Pore (MPTP) and how it ties into
both programmed and un-programmed cell death (apoptosis and necrosis, respectively).
The MPTP, normally closed, serves to establish selective membrane permeability
of the inner mitochondrial membrane, while simultaneously establishing the ionic
4

gradients necessary for proper ETC function. Conditions of oxidative stress, ATP
depletion, and Ca+2 overload are conducive to MPTP opening; these pathologic states
define ischemia, yet MPTPs generally remain closed during such an episode.
Coincidentally, the acidic cytosol, resulting from increased lactic acid, inhibits MPTP
opening. It isn’t until reoxygenation of the tissue that said lactic acid is ‘washed out’, and
conditions become ideal for the opening of MPTPs. As these pores open, calcium floods
the inner mitochondrial matrix and the resulting increase of osmotic pressure causes the
mitochondria to swell. Matrix swelling strains and, eventually, ruptures the outer
mitochondrial membrane, initiating a release of cytochrome c and pro-apoptotic proteins,
such as Bax, that lead to caspase activation and eventual cell death (Figure 2).7-10,12-15 Of
particular interest are the pro-apoptotic Bax protein and the anti-apoptotic Bcl protein
family. Bax exists within the cytosol and, when exposed to apoptotic conditions,
oligomerizes and inserts itself into the outer mitochondrial membrane; thus, facilitating a
release of additional apoptotic factors.3 Recent research has also elucidated the role of the
Bcl-2 member of the Bcl family of anti-apoptotic proteins. Not only has Bcl-2 depletion
been proven to cause apoptosis by a similar mechanism as Bax, but Bcl-2 inhibition has
been shown to sensitize MPTPs to opening, indicating that it’s induction is an important
part of defending against cell death.4 Indeed, both of these proteins have demonstrated
their potential for functioning as future therapeutic targets to minimize infarct size due to
programmed cell death.

5

Figure 2. Pathophysiology of reperfusion injury. Chain of events that occur during
reperfusion injury, ultimately resulting in myocardial apoptosis.
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Apoptotic myocardium is most commonly found at the periphery of the infarct region, as
the vast majority of the center is comprised of necrotic tissue. The duration of MPTP
opening is variable among cells experiencing reperfusion, and plays an integral role in the
determination of infarct size.16,17 As the pores remain open, oxidative phosphorylation
becomes unavailable to the mitochondria, and the F1F0 begins to function in reverse; ATP
synthesis reverses into hydrolysis. If the pores are unable to close before too much ATP is
expended, the myocyte will be unable to perform apoptosis and will, instead, become
necrotic, causing severe damage to the myocardium.7
Additionally, rapid reperfusion brings with it a flood of reactive oxygen species
(ROS) produced by the freshly fueled ETC, as well as endothelial xanthine oxidase, large
doses of nitric oxide, and NADPH oxidase secreted by neutrophils recruited by MPTP
opening. The ROS serve to cause additional damage to membranes, as well as damage the
cell’s sarcoplasmic reticulum. These ruptures in the SR cause an additional spike in [Ca+2]i,
causing further mitochondrial swelling, and myofibril hypercontracture.7,16,17 Despite these
challenges, reperfusion remains the best treatment method available for ischemic heart
injury. It’s mechanisms are complex, possessing an intricate series of events that beckon
for additional scientific refinement. What is certain, however, is that all of these
mechanisms converge on the fate of the mitochondria, an organelle that is highly
susceptible to manipulation of metabolic regulatory systems.

1.4 Mammalian Target of Rapamycin (mTOR)
7

Mammalian Target of Rapamycin (mTOR) is a Serine-Threonine kinase whose
primary function is to act as an intracellular sensor to environmental energy and nutrient
cues. Responding to these signals, mTOR catalyzes cellular transitions between catabolic
and anabolic states, thereby controlling cell growth and metabolism.18-22 By relying on
nutrient-based signaling, altered metabolic states, such as diabetes mellitus, have a
tendency to misregulate mTOR and cause cellular dysfunction. Likewise, mTOR pathway
malfunctions frequently lead to metabolic diseases, such as Type II Diabetes. It has
garnered a great deal of interest due to its multifaceted role in a variety of fields such as
metabolic stress, aging, oncology, neurodegeneration, and cardiovascular disease (Figure
3).19-25 Discoveries have shown that the mTOR protein interacts with a collection of
proteins to form two distinct complexes: the aptly named mTOR Complex 1 (mTORC1)
and mTOR Complex 2 (mTORC2) (Figure 4).22,26,27
Central to both complexes is mTOR, a member of the phosphoinositide 3-kinase
(PI3K)-related protein kinase (PIKK) family.28 Additionally, both complexes also contain
DEPTOR (DEP domain containing mTOR-interacting protein), the Tti1-Tel2 complex, and
the mLST8 (mammalian lethal with sec-13 protein 8) catalytic mTOR subunit. Unique to
mTORC1 are Raptor (regulatory-associated protein of mTOR) and PRAS40 (proline-rich
Akt Substrate), whereas mTORC2 contains Rictor (rapamycin-insensitive companion of
mTOR) and mSin1 (mammalian stress-activated MAP kinase-interacting protein 1).21,26
mTORC1 responds to the presence of nutrients and amino acids, activating the
Rheb GTPase that is responsible for releasing PRAS40 inhibition from the Raptor
8

Figure 3. mTOR relevance across multiple fields of study. The mTOR protein has been
found to play a significant role in a myriad of different fields.

9

Figure 4. Structural differences between mTORC1 and mTORC2. Venn diagram
illustrating both the common and unique components of mTORC1 and mTORC2. Both
complexes contain the mTOR protein, as well as mLST8, DEPTOR, and the Tti-Tel2
complex. Additionally, mTORC1 contains the Raptor and PRAS40 subunits while
mTORC2 is bound to Rictor and mSin1.
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subunit.29,30 It promotes translation, ribosome biogenesis, and autophagy by regulating two
major downstream targets: The eIF4E-binding protein 1 (4FBP1) and ribosomal P70S6K
(S6).31 4FBP1 controls cap-dependent translation initiation whereas S6 oversees
elongation; their activation occurs by phosphorylation. Furthermore, S6 is a potent
inhibitor of autophagy, and an excellent measure of mTORC1 function.21,26,32
mTORC2 is respondent to growth factors, promoting cell-cycle entry, cell survival,
actin cytoskeleton polarization and anabolic synthesis.26,33-35 Downstream targets of
mTORC2 are the Ser-Thr kinases Akt, PKC, and SGK. Phosphorylated at Ser473, Akt is a
major component of the mTOR cell survival cycle, responsible for downstream inhibition
of Beclin-1 mediated autophagy, crosstalk with mTORC1, and anti-apoptotic Bcl-2
induction/Bax inhibition in conjunction with abolishing p53.36 Selective manipulation of
the mTOR pathway has yielded promising results in the search for more effective methods
of cardioprotection (Figure 5). Rapamycin is one such method, the original antagonist from
which TOR’s name was derived.

1.5 Role of mTOR in I/R injury
mTOR is responsible for regulating the cellular response to conditions of energy
deprivation and ischemia.37 During these stressful situations, mTORC1 is frequently
inhibited in order to promote cell survival. Partial inhibition of mTORC1 activates cellular
autophagy, while also maintaining energy reserves by scaling down energy-depleting

11

Figure 5. mTOR signaling pathways. Schematic detailing mechanisms of the PI3K-AktmTOR signaling pathway and how it is affected by Rapamycin.
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metabolic processes.17,25,38,39 It has been demonstrated that Rheb-dependent mTORC1
inhibition plays a major role in cardioprotection.40 Downstream inhibition of S6K allows
for autophagy activation and inhibition of protein synthesis, reducing ischemic damage and
preserving cardiac function.
Conversely, mTORC2 inhibition increases infarct size in the ischemic heart.41 In
fact, activation of mTORC2 has been proven to yield cardioprotective results via Aktmediated cell survival mechanisms. While overexpression of mTORC2 serves to reduce
infarct size, genetic inhibition of Akt has shown some preserved cardioprotective function.
Thus, it has been inferred that mTORC2 cardioprotection operates via both Akt-dependent
and –independent mechanisms.42,43 mTOR inhibition with rapamycin induces potent
preconditioning-like effects against myocardial I/R injury by limiting infarct size and
cardiomyocyte necrosis and apoptosis.23 Furthermore, the immunosuppressant drug
Rapamycin has been shown to have cardioprotective properties by inhibiting mTORC1
function and inducing optimum levels of autophagy (Figure 6).44

1.6 Rapamycin
Rapamycin (Sirolimus®) is an anti-fungal macrolide derived from the Streptomyces
hygroscopicus bacterial strain. Originally isolated from a soil sample from the Eastern
Islands in the 1970s, the drug proved to be a valuable research tool in studying cell growth
and proliferation.18 Technological advances in the 1990s made way for the discovery of
Rapamycin’s action on the mTOR complex in yeast and, shortly thereafter, mammals.45-49
13

Figure 6. mTOR-mediated cardioprotection. Both selective inhibition of mTORC1 and
the activation of mTORC2 yield cardioprotective benefits.
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It displays a remarkable ability to halt cell growth and has been adopted as an effective
immunosuppressant used to coat post-angioplasty drug-eluting stents (to reduce the risk of
restenosis), as well as prevent rejection of coronary artery grafts and organ transplants.50-53
Rapamycin interferes with mTOR function by the blockade of the crowded ATPbinding catalytic domain of the mTOR complex. Flanked by a large N- and
C-terminal lobe on either side, this hydrophobic active site lies within a deep valley and is
responsible for drawing in and phosphorylating mTOR’s downstream substrates.22 In the
presence of the drug, Rapamycin’s direct binding target, FK506-binding protein 12
(FKBP12) forms a ternary complex with the FRB domain of mTOR.6,37 The end result is
catalytic domain occlusion, and allosteric inhibition of MTORC1; mTORC2 function is
not affected by normal doses of Rapamycin.22,24,26,31 Recent studies have shown the
effectiveness of ATP-competitive inhibitors, such as the anticancer agent Torin2, which
inhibits both mTORC1 and mTORC2.38,53 These inhibitors have assisted in understanding
the delicate balance involved between the two mTOR complexes their complex signaling
networks. mTOR participates in crosstalk between both the PI3K-Akt and MAPK signal
transduction pathways.16,17
In 2006, the cardioprotective effect of rapamycin against I/R injury in isolated
mouse heart and cardiomyocytes was first reported.23 Attenuation of I/R injury with
rapamycin is mediated through opening of mitochondrial KATP channels (ATP-sensitive
potassium channel). Soon thereafter, further signaling mechanisms in rapamycin-induced
15

cardioprotection were identified. Rapamycin triggered unique cardioprotective against I/R
injury signaling through JAK2-STAT3 signaling.54 This study showed the ERK-dependent
phosphorylation of STAT3, which is causatively involved in reducing I/R injury in the
heart and cardiomyocytes. Rapamycin also causes a significant increase in phosphorylation
of GSK3β at Ser9, inactivating the protein.55 It has been shown that activation of GSK3β
induces myocardial apoptosis by increasing mitochondrial depolarization and releasing
cytochrome C and eventual cell death. Inhibition of GSK3β activation induces
cardioprotection during I/R by regulating the MPTP opening through direct
phosphorylation.
Pro-apoptotic proteins, such as Bax, and anti-apoptotic proteins, including Bcl-2, are
responsible for MPTP regulation in situations of cellular stress, tipping the balance
between cell death or survival. Rapamycin enhances the prosurvival Bcl-2 to Bax ratio by
inactivating GSK3β, which may mediate rapamycin-induced cardioprotection against I/R
injury.54
The major goal of this study was to further elucidate the role of Rapamycin, in
conjunction with reperfusion therapy and to understand the associated signaling pathways
with cardioprotection. We believe that these studies will help us in future translation of the
concept of mTOR inhibition in cardioprotection in the clinical setting.

16

Materials and Methods
2.1 Chemicals and Reagents
Rapamycin (Sirolimus®) was purchased from LC Laboratories (MA). ApoAlertTM
DNA Fragmentation Assay kit was purchased from BD Biosciences, Palo Alto, CA. DAPI
was purchased from Vector Laboratories, Inc. CA. Antibodies for phospho-serine 473-Akt,
Akt, p-S6, S6, phospho-tyrosine 705-STAT3, STAT3, p-ERK1/2, ERK1/2, p-JNK1/2,
JNK1/2, p-P38, P38, Bcl-2, and Bax were purchased from Cell Signaling Technology and
GAPDH-HRP was purchased from Santa Cruz Biotechnology.

2.2 Animals
Adult C57BL/6J mice (body weight ~30 g) were supplied by Jackson Laboratories.
The animal care and experiments were approved by the Institutional Care and Use
Committee of Virginia Commonwealth University.

2.3 Experimental Groups
For in vivo regional I/R protocol, 3 groups were used: 1) DMSO without I/R, 2)
DMSO with I/R, or 3) Rapamycin (0.25 mg/kg) with I/R. DMSO/Rapamycin was injected
(intracardial) immediately at the onset of reperfusion following 30 min of in situ ischemia
(Figure 7).
17

2.4 Myocardial Infarction Protocol
The in vivo myocardial I/R procedures were conducted in mouse by ligation of the
left anterior descending coronary artery (LAD) according to a previously reported
method.19 To simulate ischemia, animals were anesthetized with pentobarbital sodium (70
mg/kg, i.p.), and ventilated on a positive pressure ventilator. A left thoracotomy was
performed at the fourth intercostal space, and the heart was exposed by stripping the
pericardium. The LAD was occluded for 30 min by a 7.0 silk ligature that was placed
around it and a small piece of polyethylene tubing (PE10) that was positioned on top of it.
Reperfusion was established by removing the PE10 tube that was compressing the LAD.
Just prior to reperfusion, a bolus of Rapamycin (0.25 mg/kg, i.c.) or DMSO (0.2 mL, i.c.)
was injected intracardially (Figure 7). Air was then expelled from the chest, and the chest
cavity was closed. The animal was placed into a cage on a heating pad until fully
conscious, and left to reperfuse for 24 hours.

2.5 Measurement of Infarct Size
The heart was removed following 30 min of ischemia and 24 hr of reperfusion, and
mounted on a Langendorff apparatus. The coronary arteries were perfused with 37°C
Krebs-Henseleit buffer. After the blood was washed out, 3 ml of 10% TTC in isotonic
phosphate buffer (pH 7.4) at 37°C were infused over several minutes before the ligature

18

Figure 7. Experimental design. Experimental groups and protocol of regional I/R by
LAD occlusion in C57 mouse hearts.
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was retightened and ~1 ml of 5% Phthalo blue dye was injected as a bolus into the aorta
until most of the heart turned blue. The heart was perfused with saline to wash out the
from apex to base of equal thickness (~1 mm). The slices were then fixed in 10% neutral
buffered formaldehyde for 4 to 24 h with a weight on top to keep the heart slices flat for
the initial 30 min. The areas of infarcted tissue, the risk zone, and the whole left ventricle
were determined by computer morphometry using ImageJ imaging software.

2.6 Apoptosis Assay
Apoptosis was determined by TUNEL staining using an ApoAlertTM DNA
Fragmentation Assay kit purchased from BD Biosciences according to previously reported
protocol.56 Hearts were stored in a 10% formalin solution, and paraffin–embedded tissue
section was mounted on glass slides. Apoptosis was then assessed in the transverse
sections of paraffin sections. Sections were deparaffinized by immersing slides in fresh
xylenes. The slides were then immersed in 96% ethanol, 90% ethanol and 80% ethanol for
5 min each. The sections were rehydrated by immersing in distilled water for 3-5 min
which was followed by immersion in citrate buffer (pH 6.0) and boiled for 10 min. Slides
were then incubated with nucleotide mix, TdT enzyme in equilibration buffer according to
manufacturer’s protocol (BD Biosciences, CA) for 1 hr at 370C under dark. The reaction
was terminated by immersing slides in 2XSSC buffer for 15 min. After three wash cycles
with PBS (phosphate saline buffer), tissue sections on slides were incubated in mounting
medium for fluorescence with DAPI (Vector Laboratories, Inc. CA). The sections were
20

then covered with a glass coverslip. Apoptotic cells were examined under a fluorescence
microscope (Nikon Eclipse Ti) which were clearly identified with a strong nuclear green
fluorescence. All cell nuclei were visualized as blue fluorescence following staining with
DAPI. The apoptotic index was expressed as the number of apoptotic cells of all
cardiomyocytes per field (n=3). Apoptotic rate in the peri-infarct regions was calculated
using 6 random fields, which is primarily composed of the peri-infarct area.56

2.7 Western Blots
Total soluble protein was extracted from the whole heart tissue with extraction
buffer. Seventy-five (75 ug) protein from each sample was separated by SDS-PAGE and
transferred onto nitrocellulose membrane (0.2 um pore size). The membrane was incubated
in cold conditions overnight with primary antibodies (phospho-serine 473-Akt, Akt, p-S6,
S6, phospho-tyrosine 705-STAT3, STAT3, p-ERK1/2, ERK1/2, p-JNK1/2, JNK1/2, pP38, P38, Bcl-2, and Bax from Cell Signaling Technology; GAPDH-HRP from Santa Cruz
Biotechnology) in a 1:1000 dilution with 5% BSA. The membrane was washed and
incubated with horseradish peroxidase conjugated secondary antibody (1:3000 dilution in
5% milk solution) and the blots were developed using a chemiluminescent system
(Western Lighting Plus-ECL; Perkin Elmer, Inc.).

2.8 Data Analysis and Statistics

21

Data are presented as mean±SEM. The differences between groups were analyzed
with one-way analysis of variance followed by Student-Newman-Keuls post hoc test for
pairwise comparison, or by unpaired t-test. P<0.05 was considered to be statistically
significant. All statistical analyses were performed using Prism statistical software.
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Results

3.1 Rapamycin reduces infarct size
Rapamycin treatment at the onset of reperfusion resulted in a significant reduction
in infarct size (% of risk area) to a mean of 28.2±1.2 as compared to 46.1±2.7 in the
DMSO-treated control group (n=4, p<0.01) after 30 min ischemia and 24 hour reperfusion
(Figure 3B). Total risk area was not statistically different between Rapamycin (60.0%±2.3)
and DMSO (54.5%±1.2) treated groups (n=4, p>0.05) following in vivo I/R (Figure 8A).

3.2 Effect of Rapamycin on Myocardial Apoptosis
Tissue sections from Rapamycin treated hearts showed a significant reduction in
TUNEL-positive nuclei in the peri-infarct regions. The Rapamycin group decreased to
3.4±1.0% as compared to 10.0±1.3% in the DMSO-treated group (n=3, p<0.05) (Figure 9A
and B).

3.3 Rapamycin inhibits mTORC1 and promotes mTORC2 activity
To further elucidate the effects of Rapamycin on mTOR, S6 and Akt
phosphorylation levels were analyzed by Western Blot to gauge mTORC1 and mTORC2
activity, respectively. S6 phosphorylation at Ser 235/236 displayed an increasing trend
among samples in the DMSO-treated I/R group, compared to control (no I/R) C57 mouse
23

hearts. This phosphorylation was significantly reduced with Rapamycin treatment,
displaying no major change relative to the control group (Figure 10, n=3, p<0.05). In vivo
I/R elicited no major change among Akt Ser 473 phosphorylation compared to control.
However, post-ischemic Rapamycin treatment significantly increased phosphorylation at
this site (Figure 11, n=3, p<0.01).

3.4 Ischemia/reperfusion Increases STAT3 Phosphorylation
STAT3 phosphorylation was increased in both DMSO- and Rapamycin-treated I/R
groups compared to C57 control hearts (n=3, p<0.05), with no significant changes between
the I/R groups (Figure 12A). Additionally, total STAT3 protein levels were decreased
following I/R, and restored with Rapamycin treatment (n=3, p<0.05)(Figure 12B).

3.5 Effect of Rapamycin on MAP Kinase Signal Transduction
To analyze the effect of post-ischemic Rapamycin treatment on the MAP Kinase
signaling pathway, phosphorylation levels of ERK1/2, JNK1/2, and P38 were measured
using western blot analysis. Both pERK1 and pERK2 were significantly increased
following post-ischemic Rapamycin treatment compared to the control and DMSO-treated
I/R groups (n=3, p<0.01)(Figure 8A, B, and C). Total ERK1 and 2 levels were not affected
among any of the treatment groups (n=3, p>0.05)(Figure 13A, B, and C). Phospho-P38, as
well as total P38, levels remained unchanged between control and I/R DMSO groups (n=3,
p>0.05), but significantly decreased with Rapamycin treatment (n=3, p<0.01)(Figure 14).
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While p-JNK1 and 2 did not display statistically significant changes, results showed a
substantial positive trend with in vivo I/R, and a further increase following Rapamycin
treatment (n=3, p>0.05)(Figure 15A, B, and C). Total JNK1,2 and JNK1 levels increased
following in vivo I/R, compared to the control; Rapamycin did not appear to alter this
elevated state of expression (n=3, p<0.05)(Figure 15E and F). Total JNK2, alone, yielded a
similar trend, but results were not statistically significant (n=3, p>0.05)(Figure 15G).

3.6 Rapamycin Blocks Pro-Apoptotic Bax Signaling
Bcl-2 and Bax levels were measured to identify pro-survival and pro-apoptotic cell
signaling, respectively. Bcl-2 levels decreased following I/R, which showed only a positive
increasing trend following Rapamycin treatment (n=3, p<0.05)(Figure 16A). Pro-apoptotic
Bax was significantly increased following in vivo I/R (n=3, p<0.05), but its expression was
reduced to a pre-ischemic state with post-ischemic Rapamycin administration (n=3,
p<0.01)(Figure 16A). The Bcl-2/Bax ratio showed significant decline in both I/R groups
(n=3, p<0.05); however, there was an increasing trend in the Rapamycin treatment group
(Figure 16B).
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Figure 8. Effect of Rapamycin on infarct size. (A) Infarct region was determined by
tetrazolium chloride (TTC) assay after in vivo I/R. Infarct size was then calculated as a %
of the total measured risk area. *p<0.01 vs DMSO, n=4 (B) Risk area measurement,
obtained via Evans Blue assay, as % of total tissue sample, n=4.
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Figure 9. Effect of Rapamycin treatment on myocardial apoptosis. Myocardial
apoptosis was determined by TUNEL assay following in vivo I/R. (A) Representative
images of TUNEL-positive nuclei in bright green fluorescent color (White arrows) and
total nuclei staining with 4,5-diamino-2-phenylindole (DAPI). (B) Bar graph showing
quantitative data of TUNEL positive nuclei in myocardium. *p<0.05 vs DMSO, n=3 per
group. Refer to Fig. 1 for drug treatment schedules and I/R protocol.
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Figure 10. Rapamycin (RAPA) attenuates phosphorylation of S6 Ser235/236. (A)
Representative immunoblots for p-S6, total S6, and GAPDH expression in whole heart
tissue samples after in vivo I/R (no I/R in C57 control). (B) Densitometry analysis of
immunoblots for the ratio of p-S6/S6. *p<0.05 vs I/R, n=3. (C) Densitometry analysis of
immunoblots for the ratio of S6/GAPDH,**p<0.01 vs all other groups, n=3.
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Figure 11. Rapamycin (RAPA) enhances phosphorylation of Akt Ser473. (A)
Representative immunoblots for p-Akt, total Akt, and GAPDH expression in whole heart
tissue samples after in vivo I/R (no I/R in C57 control). (B) Densitometry analysis of
immunoblots for the ratio of p-Akt/Akt. **p<0.01 vs all other groups, n=3. (C)
Densitometry analysis of immunoblots for the ratio of Akt/GAPDH, n=3.
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Figure 12. In vivo I/R induces STAT3 phosphorylation while Rapamycin shows no
significant changes. (A) Representative immunoblots for p-STAT3, total STAT3, and
GAPDH expression in whole heart tissue samples after in vivo I/R (no I/R in C57 control).
(B) Densitometry analysis of immunoblots for the ratio of p-STAT3/STAT3. *p<0.05 vs
C57 control, n=3. (C) Densitometry analysis of immunoblots for the ratio of
STAT3/GAPDH. *p<0.05 vs C57 control, n=3.
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Figure 13. Rapamycin (RAPA) induces ERK phosphorylation following I/R. (A)
Representative immunoblots for p-ERK1,2, p-ERK1, p-ERK2, total ERK1,2, ERK1,
ERK2, and GAPDH expression in whole heart tissue samples after in vivo I/R (no I/R in
C57 control). (B) Densitometry analysis of immunoblots for the ratio of pERK1,2/ERK1,2. **p<0.01 vs all other groups, n=3. (C) Densitometry analysis of
immunoblots for the ratio of pERK1/ERK1, **p<0.01 vs all other groups, n=3. (D)
Densitometry analysis of immunoblots for the ratio of pERK2/ERK2,**p<0.01 vs all other
groups, n=3. (E)(F)(G) Densitometry analysis of immunoblots for the ratio of total ERK
variants relative to GAPDH, n=3.
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Figure 14. Rapamycin (RAPA) decreases P38. (A) Representative immunoblots for pP38, total P38, and GAPDH expression in whole heart tissue samples after in vivo I/R (no
I/R in C57 control). (B) Densitometry analysis of immunoblots for the ratio of p-P38/P38.
*p<0.01 vs all other groups, n=3. (C) Densitometry analysis of immunoblots for the ratio
of S6/GAPDH,*p<0.01 vs all other groups, n=3.
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Figure 15.

Ischemia/reperfusion (I/R) increases total JNK – modulation of its

phosphorylation by Rapamycin. (A) Representative immunoblots for p-JNK1,2, p-JNK1,
p-JNK2, total JNK1,2, JNK1, JNK2, and GAPDH expression in whole heart tissue samples
after in vivo I/R (no I/R in C57 control). (B)(C)(D) Densitometry analysis of immunoblots
for the ratio of JNK phosphorylation compared to total protein levels, n=3. (E)(F)(G)
Densitometry analysis of immunoblots for the ratio of total ERK variants relative to
GAPDH. *p<0.05 vs C57 control, n=3.
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Figure 16. Rapamycin (RAPA) decreases Bax levels in adult C57 mouse hearts. (A)
Representative immunoblots for Bcl-2, Bax, and GAPDH expression in whole heart tissue
samples after in vivo ischemia/reperfusion (I/R); (no I/R in C57 control). (B)
Densitometry analysis of immunoblots for the Bcl-2/Bax ratio. *p<0.01 vs C57 control,
n=3. (C) Densitometry analysis of immunoblots for the ratio of Bcl2/GAPDH,*p<0.01 vs
control, **p<0.01 vs control, n=3. (D) Densitometry analysis of immunoblots for the ratio
of Bax/GAPDH,**p<0.01 vs control, *p<0.05 vs I/R, n=3.

34

Discussion
Cardiovascular disease is the current leading cause of death among the Western
nations. In 2007, almost 8 million individuals were affected by acute myocardial infarction
(AMI).57 Clinically the goal is to re-establish blood flow to the ischemic area as quickly as
possible to salvage cardiomyocytes that would be damaged by ischemia. While reperfusion
is necessary for tissue survival, it is worth noting that reperfusion itself can also cause
tissue damage, termed “reperfusion injury”. As more tissue is irreversibly injured, the
prognosis becomes worse because terminally differentiated cardiac myocytes cannot
regenerate. Loss of contractile mass puts an inordinate load on surviving tissue thereby
causing the remaining cells to hypertrophy resulting in adverse remodeling of the ventricle
ending ultimately in heart failure. Therefore, strategies that would render heart cells
resistant to death from ischemia/reperfusion injury would greatly improve the prognosis of
AMI.
In the present study, we investigated the cardioprotective mechanisms during postischemic Rapamycin treatment in adult mouse hearts. Furthermore, we interrogated the
mTOR complex, and it’s involvement with downstream PI3K-Akt and MAPK signaling
pathways due to their role in cell survival. Rapamycin, an mTOR antagonist, has drawn
attention from it’s ability to selectively inhibit mTORC1, making it a potential therapeutic
agent.7 Activation of anti-apoptotic proteins has been shown to play an integral role in
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cardioprotection, and pre-treatment with Rapamycin has been shown to reduce both the
infarct size in the heart and cardiomyocyte apoptosis following simulated ischemia and
reperfusion.19,23,54,56 However, in direct contrast to studies outlining it’s benefits,
Rapamycin has been shown to abolish the cardioprotective effects of pharmacological
preconditioning, by increasing infarct size.19,23,54,56 The present study demonstrates
Rapamycin-induced cardioprotection in vivo, as evidenced by decrease in myocardial
infarct size and reduced level of apoptosis in the heart. We believe that these in vivo
studies are highly relevant for potential clinical translation of cardioprotective Rapamycin
treatment.
Our results showed marked decrease in infarct size as a result of Rapamycin
treatment at the onset of reperfusion. Furthermore, apoptotic cell death was decreased,
indicating an induction in pro-survival protein cascades and/or inhibition of pro-apoptotic
pathways. The infarct region is deadly both during the AMI, and after, as it has the
potential to drive the heart into pathological remodeling. Improper cardiac hypertrophy or
ventricular dilation drastically impede the contractile ability of the heart, often leading to
heart failure, and death.5 However, cardiac remodeling is an important stress recovery
mechanism and, while too much can be deadly, too little would result in a much quicker
death.
mTOR serves to regulate anabolic and catabolic cellular states, and provide a
therapeutic target with which to facilitate proper myocardial recovery. It plays a key role in
cardioprotective pressure-induced cardiac hypertrophy, and complete deletion of mTOR
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has been proven to cause lethal dilated cardiomyopathy.19,22,31 mTOR is divided into two
distinct complexes: the Rapamycin-sensitive mTORC1 and the Rapamycin-insensitive
mTORC2. In the present study, S6 phosphorylation (by mTORC1) exhibited an increasing
trend following in vivo I/R, suggesting that mTORC1 activation is the primary complex
stimulated during I/R injury. Following Rapamycin treatment, the dramatic decrease of
pS6 and total S6 further substantiates this. S6 is an upstream inhibitor of autophagy,
allowing us to infer that as Rapamycin interferes with mTORC1 and increased autophagy
levels may offer some cardioprotective benefit during reperfusion. Akt, the downstream
target of mTORC2, promotes cell survival and cytoskeletal growth, as well as restricting
Beclin-1 function.36 Our results showed Akt phosphorylation was significantly increased
with Rapamycin. Thus, while mTORC1 inhibition appears to assist with the minimization
of reperfusion injury, mTORC2 activation plays a dominant role in I/R cardioprotection.
In addition to the PI3K-Akt signaling pathway, the MAPK family of kinases also
regulate cell survival and cell death. JNK and P38 MAPK are the members of the stresssensitive kinase family that respond to various environmental stimuli such as cytokines,
radiation, and reactive oxygen species. The MAPKs regulate the critical cellular processes
such as gene transcription, cytoskeletal organization, metabolic homeostasis, cell growth,
and apoptosis via a complex signal transduction cascade, which most likely occurs by
phosphorylation of some common downstream target proteins. Although it is generally
agreed that P38 MAPK plays a pivotal role in the signaling mechanisms of I/R injury, the
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question of whether p38 MAPK phosphorylation is protective or detrimental continues to
be debatable.
JNK and P38 also act as mediators of P53 activation and cell death in response to
stress and DNA damage, noting a marked increase during events such as I/R.3,4 ERK, also
a downstream target of Akt, exhibits both pro-survival and pro-apoptosis characteristics,
but recent research has shown significant ERK induction during Rapamycin-facilitated
preconditioning.19 In the present study, total JNK levels were significantly increased with
in vivo I/R exposure, but were not affected by Rapamycin. Our data showing attenuation of
P38 phosphorylation in the Rapamycin treatment group contradicts earlier literature, but
provides direct evidence that P38 and, most likely, P53-mediated cell death are inhibited
by Rapamycin. Earlier studies showing increased phosphorylation of ERK with
Rapamycin were supported by our results, and are indicative of pro-survival STAT3
activation.54 Additionally, a strong link can be established with mTORC2-induced Akt and
downstream ERK phosphorylation. In regards to the MAP kinases, it is apparent that
Rapamycin administered during reperfusion activates ERK, concurrently inhibits P38, and
has no significant effect on JNK in vivo.
The STAT3 protein, a member of the JAK-STAT signal cascade, is localized both
the nucleus and mitochondria. It is a downstream activation target of ERK which inhibits
MPTP opening and, therefore, apoptosis. In the diabetic model, STAT3 induction
increased with Rapamycin treatment, yet the results of this study indicated a different set
of changes in healthy mice.54,56 In these hearts, I/R appears to be the driving force for
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STAT3 induction, while the addition of Rapamycin caused no significant changes. Thus, it
appears that different metabolic states pose radically different mechanisms of damage
repair in I/R injury. Future studies are required to better compare these individual
pathways.
It has been shown that STAT3 is responsible for the upregulation of the antiapoptotic Bcl-2 and pro-apoptotic Bax mitochondrial proteins. Interestingly enough, Bcl-2
levels were not affected by Rapamycin, yet Bax did see a significant reduction in protein
expression. While there is only an upwards trending Bcl-2/Bax ratio recovery with
Rapamycin, we believe that additional signal pathways, such as the PI3K-Akt pathway,
further regulate these mitochondrial proteins.
In conclusion, we have provided several novel insights into the complex
mechanisms by which Rapamycin treatment during reperfusion bestows cardioprotective
benefits in vivo. While mTORC1 is inhibited, mTORC2 activity is amplified. Akt appears
to be the mediator between the PI3K-Akt mTOR cascade and the MAP kinases. STAT3 is
upregulated by I/R stress alone, and does not appear to play a significant role in Bcl-2/Bax
regulation compared to the PI3 kinases. At the present time, further studies are necessary to
better understand the effects of metabolic dysregulation on mTOR mediated
cardioprotection following reperfusion.
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